Gennova Biopharmaceuticals Divests mRNA Business for ₹1,395 Million

Gennova Biopharmaceuticals Limited (a subsidiary of Emcure Pharmaceuticals) has signed a Business Transfer Agreement on July 10, 2026, to execute a slump sale of its mRNA business to Immunoscript Life Science Private Limited for a lump sum cash consideration of ₹1,395 million. Key Deal Highlights: Target & Buyer: The mRNA business is being sold as a going concern to Immunoscript Life Science, a newly incorporated entity (April 2026) promoted by Dr. Sanjay Singh, a former Director of Gennova. The buyer is not part of the Emcure promoter group. Financial Scale: The divested unit is relatively small, contributing just 0.71% (₹647.10 million) to the consolidated revenue and 2.68% (₹1,326.31 million) to the consolidated net worth in FY 2025-26. Timeline: The transaction is expected to conclude by July 17, 2026, subject to standard regulatory and statutory approvals. Strategic Rationale: Portfolio Streamlining: The divestment allows Gennova to reorganize its operations and sharply focus its capital and management bandwidth on its core competencies: R&D, manufacturing, and marketing of biotechnology-based products, biosimilars, and adjacent therapeutic platforms. Clean Exit: Structured as a slump sale, it ensures a clean transfer of the business without altering the shareholding pattern of the parent company, Emcure Pharmaceuticals. Outlook: This strategic carve-out enables Gennova to optimize its balance sheet and operational focus, while the mRNA assets transition to a specialized, agile entity (Immunoscript) dedicated to advancing precision immunology and next-generation vaccines.